7 completed, 5 recruiting, 1 not yet recruiting, 1 terminated. 16 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 7, Recruiting 5, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Polyradiculoneuropathy: new trials by email Literature Review of Polyradiculoneuropathy trials Research Report on Polyradiculoneuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Obinutuzumab β - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β | Phase 1 / Phase 2 | Not yet recruiting | Zhongming Qiu | 24 | 2026-07-15 | 2026-07-10 |
| Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment KITE-363, Fludarabine, Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis | Phase 1 | Recruiting | Kite, A Gilead Company | 57 | 2026-04-10 | 2026-10-19 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders Azercabtagene zapreleucel (azer-cel) - B-cell Mediated Autoimmune Disorders | Phase 1 | Recruiting | TG Therapeutics, Inc. | 100 | 2025-05-06 | 2026-10-27 |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP KINE-101 - CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 1 | Completed | Kine Sciences Co., Ltd. | 9 | 2024-08-27 | 2026-01-20 |
| A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) CK0801 - Guillain-Barré Syndrome | Phase 1 | Withdrawn | Cellenkos, Inc. | 2022-11-01 | 2023-01-04 | |
| IVIG vs SCIG in CIDP Intravenous immune globulin G, Subcutaneous immune globulin G - CIDP, Immunoglobulin Deficiency | Phase 1 | Recruiting | Rutgers, The State University of New Jersey | 20 | 2022-09-11 | 2025-12-11 |
| Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis | Phase 1 / Phase 2 | Unknown | All Natural Medicine Clinic, LLC | 2000 | 2021-03-01 | 2021-05-26 |
| A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) ANX005, Intravenous immunoglobulin - Guillain-Barré Syndrome | Phase 1 | Completed | Annexon, Inc. | 14 | 2020-01-29 | 2021-08-11 |
| A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant - Healthy, Primary Immune Thrombocytopenia | Phase 1 | Terminated | Pfizer | 58 | 2017-07-17 | 2024-07-05 |
| Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women Group B streptococcus (GBS) vaccine- low dose, Group B streptococcus (GBS) vaccine- High dose, Placebo- Saline - Group B Streptococcus | Phase 1 | Completed | Novartis Vaccines | 678 | 2010-05-01 | 2017-05-15 |
| A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine Group B streptococcus (GBS) vaccine - Group B Streptococcus (GBS) Disease | Phase 1 | Completed | Novartis | 50 | 2010-01-01 | 2017-06-14 |
| A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine Group B streptococcus (GBS) vaccine - Group B Streptococcus (GBS) Disease | Phase 1 | Completed | Novartis Vaccines | 95 | 2010-01-01 | 2020-02-11 |
| A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age GBS glycoconjugate vaccine, Placebo - Invasive Group B Streptococcus (GBS) Disease | Phase 1 | Completed | Novartis Vaccines | 130 | 2008-02-01 | 2011-12-08 |
| A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age Monovalent GBS-CRM glycoconjugate vaccine, Placebo - Invasive Group B Streptococcus (GBS) Disease | Phase 1 | Completed | Novartis Vaccines | 65 | 2007-12-01 | 2011-12-08 |
Guillain-Barre Syndrome (8) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (8) · Disease (5) · Myasthenia Gravis (4) · Multiple Sclerosis (3) · Neuromyelitis Optica (3) · Myositis (2) · Agammaglobulinemia (1) · Ageusia (1) · Anosmia (1) · Anxiety Disorders (1) · Arthritis, Reactive (1) · Autoimmune Diseases of the Nervous System (1) · Bipolar Disorder (1) · COVID-19 stress syndrome (1)
Autoimmune Diseases (16) · Chronic Disease (16) · Demyelinating Diseases (16) · Disease Attributes (16) · Immune System Diseases (16) · Nervous System Diseases (16) · Neuromuscular Diseases (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Peripheral Nervous System Diseases (16) · Polyneuropathies (16) · Autoimmune Diseases of the Nervous System (15) · Post-Infectious Disorders (7) · Demyelinating Autoimmune Diseases, CNS (4)
Vaccines (3) · Cyclophosphamide (2) · Immunoglobulins, Intravenous (2) · fludarabine (2) · Hizentra (1)
Novartis Vaccines (4) · All Natural Medicine Clinic, LLC (1) · Annexon, Inc. (1) · Cellenkos, Inc. (1) · Kine Sciences Co., Ltd. (1) · Kite, A Gilead Company (1) · Novartis (1) · Pfizer (1) · Rutgers, The State University of New Jersey (1) · TG Therapeutics, Inc. (1) · Tianjin Medical University General Hospital (1) · Tongji Hospital (1) · Zhongming Qiu (1)
United States (5) · Switzerland (4) · Belgium (2) · China (2) · Australia (1) · Bangladesh (1) · Canada (1) · Denmark (1) · New Zealand (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Chuan Qin (1) · Daishi Tian (1) · Hanna Park (1) · Luigi Brunetti, PhD (1) · Qiang Liu, M.D.,Ph.D (1) · Tara Sadeghi (1) · Wanzhu Hou, CMD (1)
2018 (1)